TTRX (Turn Therapeutics) Long-Term Debt: $5.94 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTRX Turn Therapeutics Inc TTRX
11 GF Score
Price $7.44
View Full Analysis

What is Turn Therapeutics Long-Term Debt?

Turn Therapeutics TTRX -4.87% 11 Long-Term Debt is $5.94 Mil as of Mar. 2026. GuruFocus rates TTRX with a GF Score™ of 11/100.

Turn Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $5.94 Mil.

Turn Therapeutics's quarterly Long-Term Debt stayed the same from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($5.94 Mil).

Turn Therapeutics  (NAS:TTRX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Turn Therapeutics Long-Term Debt Related Terms

Turn Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Turn Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turn Therapeutics Long-Term Debt Chart

Turn Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Long-Term Debt
0.00 0.00 0.00

Turn Therapeutics Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 5.94
TTRX
11GF Score
Turn Therapeutics Inc TTRX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $5.94 Mil mean?
Turn Therapeutics (TTRX) has a Long-Term Debt of $5.94 Mil as of Mar. 2026.
Is Turn Therapeutics' Long-Term Debt too high?
Turn Therapeutics' current Long-Term Debt is $5.94 Mil. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' Long-Term Debt compare to IRD and VRXA?
Turn Therapeutics' Long-Term Debt of $5.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Turn Therapeutics's current Long-Term Debt is $5.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current Long-Term Debt of $5.94 Mil. The current Long-Term Debt is $5.94 Mil. Turn Therapeutics' overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current Long-Term Debt is $5.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Turn Therapeutics Business Description

Address 250 North Westlake Boulevard, Suite 210, Westlake Village, CA, USA, 91362
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score

Get the complete analysis for TTRX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.44
Price